Is [68Ga]Ga-DOTA-TATE PET/CT useful in the diagnosis of patients suspected of ectopic Cushing’s syndrome?
, 2, 13, 1
Abstract
Introduction: Ectopic Cushing’s syndrome (ECS) presents significant diagnostic and management challenges due to its varied clinical presentation and diagnostic uncertainties associated with conventional imaging methods. The aim of this study was to evaluate the effectiveness of [68Ga]Ga-DOTA-TATE positron emission tomography/computed tomography (PET/CT) in diagnosing patients suspected of ECS with negative results from conventional imaging techniques.
Material and methods: In this retrospective single-institution study, data from January 2010 to August 2023 were analysed. Patients who underwent [68Ga]Ga-DOTA-TATE PET/CT (Siemens Biograph 64) scans due to clinical and biochemical indicators of Cushing’s syndrome were included, with prior conventional imaging yielding no abnormalities. The PET/CT scans were analysed qualitatively and quantitatively for any pathological foci. The study was conducted in accordance with ethical standards and approved by the Medical University of Warsaw’s ethics committee.
Results: Of the 56 [68Ga]Ga-DOTA-TATE PET/CT scans performed on 44 patients, pathological accumulations were identified in 6 scans (11%) and 4 (9%) patients. Pathological findings were exclusively located within the thoracic cavity; lung lesions were identified in 3 patients, and 3 independent lesions within the anterior mediastinum and breast were observed in a single patient across 3 distinct scans. Histopathological analysis confirmed neuroendocrine tumours in all patients.
Conclusions: [68Ga]Ga-DOTA-TATE PET/CT demonstrated limited potential for diagnostic value in patients suspected of ECS with negative outcomes according to conventional imaging. The percentage of patients who achieved positive results (10%) was not high, although other negative tests represented a significant percentage of the patients. This study highlights the need for further research and the development of novel radiotracers to improve ECS diagnosis.
Keywords: DOTA-TATECushing syndromeectopic Cushing’s syndromesomatostatin receptorsSRIGa-DOTA-TATE[68Ga]-DOTA-TATE[18F]FDG PET/CT
References
- Balogova S, Talbot JN, Nataf V, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013; 40(6): 943–966.
- Santhanam P, Taieb D, Giovanella L, et al. PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine. 2015; 50(2): 297–305.
- Paleń-Tytko JE, Przybylik-Mazurek EM, Rzepka EJ, et al. Ectopic ACTH syndrome of different origin-Diagnostic approach and clinical outcome. Experience of one Clinical Centre. PLoS One. 2020; 15(11): e0242679.
- Wannachalee T, Turcu AF, Bancos I, et al. The Clinical Impact of [ Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumours. Clin Endocrinol (Oxf). 2019; 91(2): 288–294.
- Cieszyński Ł, Berendt-Obołończyk M, Szulc M, et al. Cushing's syndrome due to ectopic ACTH secretion. Endokrynol Pol. 2016; 67(4): 458–471.
- Papadakis GZ, Bagci U, Sadowski SM, et al. Ectopic ACTH and CRH Co-secreting Tumor Localized by 68Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2015; 40(7): 576–578.
- Bauman MMJ, Graves JP, Harrison DJ, et al. The utility of PET for detecting corticotropinomas in Cushing disease: a scoping review. Neurosurg Rev. 2023; 46(1): 160.
- Varlamov E, Hinojosa-Amaya JM, Stack M, et al. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience. Pituitary. 2019; 22(5): 445–455.
- Liu Q, Zang J, Yang Y, et al. Head-to-head comparison of Ga-DOTATATE PET/CT and F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study. Eur J Nucl Med Mol Imaging. 2021; 48(13): 4386–4395.
- Ceccato F, Cecchin D, Gregianin M, et al. The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome. Endocr Connect. 2020; 9(4): 337–345.
- Jiang Y, Liu Q, Zhu Z. 68Ga-DOTATATE PET/CT of ACTH-Independent Cushing Syndrome Due to Ectopic Adrenocortical Adenoma. Clin Nucl Med. 2023; 48(1): 83–84.
- Wang J, Luan Z, Li T, et al. Site-specific performance of Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion. Front Oncol. 2023; 13: 1204963.
- Novruzov F, Aliyev A, Wan MY, et al. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors. Eur J Hybrid Imaging. 2021; 5(1): 10.
- Wang J, Luan Z, Li T, et al. Site-specific performance of Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion. Front Oncol. 2023; 13: 1204963.
- Zidan L, Iravani A, Kong G, et al. Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on Ga-DOTATATE PET/CT and F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021; 48(1): 204–216.
- Gilis-Januszewska A, Gamrat A, Minasyan M, et al. Ectopic, CRH-responsive Cushing syndrome with negative 68Ga-DOTATATE and 18F-FDG PET/CT imaging findings and pituitary microadenoma: a challenging case with a successful outcome. Pol Arch Intern Med. 2023; 133(10).
